Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eptifibatide Versus Abciximab in Primary PCI for Acute ST Elevation Myocardial Infarction.

Next Previous
Trial Profile

Eptifibatide Versus Abciximab in Primary PCI for Acute ST Elevation Myocardial Infarction.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eptifibatide (Primary) ; Abciximab
  • Indications Embolism and thrombosis; Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms EVA-AMI
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 21 Jun 2010 Actual end date (Dec 2007) added as reported by ClinicalTrials.gov.
  • 27 Apr 2010 Actual patient number (429) added as reported by ClinicalTrials.gov.
  • 04 Jan 2008 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top